Medical Device Reporting; Malfunction Reporting Frequency, 12743-12744 [2011-5146]
Download as PDF
Federal Register / Vol. 76, No. 45 / Tuesday, March 8, 2011 / Notices
device, including, but not limited to,
implanted electrical urinary continence
devices; implanted mechanical/
hydraulic urinary continence devices;
urological clamp for males;
nonimplanted, peripheral and other
electrical continence devices; protective
garment for incontinence; surgical
mesh; electrosurgical cutting and
coagulation device and accessories;
perineometer; gynecologic laparoscope
and accessories; and vaginal pessary.
In the Federal Register of September
19, 2008 (73 FR 54406), FDA announced
the availability of the draft guidance.
Comments on the draft guidance were
due by December 18, 2008. Two
comments were received with each
comment making multiple
recommendations on changes to the
content of the guidance document.
The comments included
recommended changes to or removals of
primary, secondary, and composite
endpoints and changes to the
recommended clinical study design. In
response to these comments, FDA has
clarified the appropriate context for
recommended endpoints and a
sponsor’s options with respect to use of
a given endpoint. FDA also revised the
recommended requirements for use of
voiding diaries and clarified the
recommendation regarding the
randomization of subjects.
Comments also involved
recommendations on the categorization
of adverse events. In response to these
comments, FDA clarified the
recommendation for categorization of
adverse events as either device- or
procedure-related.
srobinson on DSKHWCL6B1PROD with NOTICES
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the Agency’s
current thinking on clinical
investigations of devices intended to
treat urinary incontinence. It does not
create or confer any rights for or on any
person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statute and regulations.
III. Electronic Access
Persons interested in obtaining a copy
of the guidance may do so by using the
Internet. A search capability for all
CDRH guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.regulations.gov. To
receive ‘‘Clinical Investigations of
VerDate Mar<15>2010
19:12 Mar 07, 2011
Jkt 223001
Devices Indicated for the Treatment of
Urinary Incontinence,’’ you may either
send an e-mail request to
dsmica@fda.hhs.gov to receive an
electronic copy of the document or send
a fax request to 301–847–8149 to receive
a hard copy. Please use the document
number 1636 to identify the guidance
you are requesting.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR part 812 have been approved
under OMB control number 0910–0078;
the collections of information in 21 CFR
part 807, subpart E, have been approved
under OMB control number 0910–0120;
the collections of information in 21 CFR
part 814 have been approved under
OMB control number 0910–0231; and
the collections of information in 21 CFR
parts 50.23 and 56.115 have been
approved under OMB control number
0910–0130.
V. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES), either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: March 2, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–5148 Filed 3–7–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0097]
Medical Device Reporting; Malfunction
Reporting Frequency
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is clarifying that
device manufacturers and importers of
SUMMARY:
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
12743
all devices, including class I and those
class II devices that are not permanently
implantable, life supporting, or life
sustaining, must continue to submit
malfunction reports in full compliance
with FDA’s Medical Device Reporting
regulation, pending future FDA notice
under the Federal Food, Drug, and
Cosmetic Act (the FD&C Act).
DATES: Submit either electronic or
written comments by May 9, 2011.
ADDRESSES: Submit electronic
comments on this document to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Identify
comments with the docket number
found in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT:
Victoria Schmid, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 3236, Silver Spring,
MD 20993–0002, 301–796–6108.
I. Background
Title II, section 227 of the Food and
Drug Administration Amendments Act
of 2007 (FDAAA) (Public Law 110–85),
amended section 519(a) of the FD&C Act
(21 U.S.C. 360i(a)), relating to the
reporting of malfunctions to FDA under
part 803 (21 CFR part 803). The
malfunction reporting requirements for
class III devices and those class II
devices that are permanently
implantable, life supporting, or life
sustaining were not altered by FDAAA.
Under the amended section 519(a),
device manufacturers and importers are
to continue to submit malfunction
reports in accordance with part 803 for
all class III devices and for those class
II devices that are permanently
implantable, life supporting, or life
sustaining, unless the Secretary of
Health and Human Services (the
Secretary) (and, by delegation, FDA)
grants an exemption, variance from, or
an alternative to, a requirement under
such regulations under § 803.19 (section
519(a)(1)(B)(i) of the FD&C Act).
However, FDAAA changed
malfunction reporting requirements for
class I devices and those class II devices
that are not permanently implantable,
life supporting, or life sustaining. Under
section 519(a) of the FD&C Act, as
amended by FDAAA, the Secretary
(and, by delegation, FDA) is required to
publish a notice in the Federal Register
or send a letter to the person who is the
manufacturer or importer of a class I
device or a class II device that is not
permanently implantable, life
E:\FR\FM\08MRN1.SGM
08MRN1
12744
Federal Register / Vol. 76, No. 45 / Tuesday, March 8, 2011 / Notices
srobinson on DSKHWCL6B1PROD with NOTICES
supporting, or life sustaining, if FDA
finds that such a device should be
subject to part 803 in order to protect
the public health (section
519(a)(1)(B)(i)(III) of the FD&C Act). If
such class I or class II devices are not
the subject of an FDA notice or letter,
the malfunction reports for these
devices are to be submitted in
accordance with the criteria established
by the Secretary (and, by delegation,
FDA), which criteria shall require the
reports to be in summary form and
made on a quarterly basis (section
519(a)(1)(B)(ii) of the FD&C Act).
Under section 519(a) of the FD&C Act,
as amended by FDAAA, there is no
change to the obligation for an importer
to submit malfunction reports to the
manufacturer in accordance with part
803 for devices that it imports into the
United States (section 519(a)(1)(B)(iii) of
the FD&C Act).
FDA intends to provide notice in the
Federal Register that lists the types of
devices that should be subject to part
803 in order to protect the public health,
as required by section 519(a)(1)(B)(i)(III)
of the FD&C Act). In addition, FDA
intends to, by rulemaking, establish
malfunction reporting criteria for
devices subject to section 519(a)(1)(B)(ii)
of the FD&C Act. In the interim, in the
interest of public health, FDA is
publishing this notice under section
519(a)(1)(B)(i)(III), to clarify that, to the
extent there is any confusion as to
current malfunction reporting
requirements, all device manufacturers
and importers of class I and those class
II devices that are not permanently
implantable, life supporting, or life
sustaining, must continue to report in
full compliance with part 803, pending
further FDA notice under section
519(a)(1)(B)(i)(III), as to specific devices
or device types subject to part 803, and
the establishment of criteria in
accordance with section 519(a)(1)(B)(ii).
FDA considers it necessary to subject all
such devices to part 803 in the interim,
in order to protect the public health by
ensuring that there is no gap in
malfunction reporting for any device.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) either electronic or written
comments regarding this document. It is
only necessary to send one set of
comments. It is no longer necessary to
send two copies of mailed comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
VerDate Mar<15>2010
19:12 Mar 07, 2011
Jkt 223001
[FR Doc. 2011–5146 Filed 3–7–11; 8:45 am]
Dated: March 2, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
BILLING CODE 4160–01–P
[FR Doc. 2011–5228 Filed 3–7–11; 8:45 am]
Dated: March 2, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute On Deafness and
Other Communication Disorders;
Notice of Closed Meetings
National Center for Complementary &
Alternative Medicine; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; Clinical
Trials—Communications.
Date: March 31, 2011.
Time: 12 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6120
Executive Blvd., Rockville, MD 20852.
(Telephone Conference Call.)
Contact Person: Christine A. Livingston,
PhD, Scientific Review Officer, Division of
Extramural Activities, National Institutes of
Health/NIDCD, 6120 Executive Blvd.—MSC
7180, Bethesda, MD 20892, (301) 496–8683,
livingsc@mail.nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; P50 Grant
Review.
Date: April 8, 2011.
Time: 11 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6120
Executive Blvd., Rockville, MD 20852.
(Telephone Conference Call.)
Contact Person: Christine A. Livingston,
PhD, Scientific Review Officer, Division of
Extramural Activities, National Institutes of
Health/NIDCD, 6120 Executive Blvd.—MSC
7180, Bethesda, MD 20892, (301) 496–8683,
livingsc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Name of Committee: National Center for
Complementary and Alternative Medicine
Special Emphasis Panel, NCCAM Education
Panel.
Date: March 24–25, 2011.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Peter Kozel, PhD.,
Scientific Review Officer, NCCAM, 6707
Democracy Boulevard, Suite 401, Bethesda,
MD 20892–5475, 301–496–8004,
kozelp@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Dated: March 2, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–5226 Filed 3–7–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\08MRN1.SGM
08MRN1
Agencies
[Federal Register Volume 76, Number 45 (Tuesday, March 8, 2011)]
[Notices]
[Pages 12743-12744]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-5146]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0097]
Medical Device Reporting; Malfunction Reporting Frequency
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is clarifying that
device manufacturers and importers of all devices, including class I
and those class II devices that are not permanently implantable, life
supporting, or life sustaining, must continue to submit malfunction
reports in full compliance with FDA's Medical Device Reporting
regulation, pending future FDA notice under the Federal Food, Drug, and
Cosmetic Act (the FD&C Act).
DATES: Submit either electronic or written comments by May 9, 2011.
ADDRESSES: Submit electronic comments on this document to https://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Victoria Schmid, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, rm. 3236, Silver Spring, MD 20993-0002, 301-
796-6108.
I. Background
Title II, section 227 of the Food and Drug Administration
Amendments Act of 2007 (FDAAA) (Public Law 110-85), amended section
519(a) of the FD&C Act (21 U.S.C. 360i(a)), relating to the reporting
of malfunctions to FDA under part 803 (21 CFR part 803). The
malfunction reporting requirements for class III devices and those
class II devices that are permanently implantable, life supporting, or
life sustaining were not altered by FDAAA. Under the amended section
519(a), device manufacturers and importers are to continue to submit
malfunction reports in accordance with part 803 for all class III
devices and for those class II devices that are permanently
implantable, life supporting, or life sustaining, unless the Secretary
of Health and Human Services (the Secretary) (and, by delegation, FDA)
grants an exemption, variance from, or an alternative to, a requirement
under such regulations under Sec. 803.19 (section 519(a)(1)(B)(i) of
the FD&C Act).
However, FDAAA changed malfunction reporting requirements for class
I devices and those class II devices that are not permanently
implantable, life supporting, or life sustaining. Under section 519(a)
of the FD&C Act, as amended by FDAAA, the Secretary (and, by
delegation, FDA) is required to publish a notice in the Federal
Register or send a letter to the person who is the manufacturer or
importer of a class I device or a class II device that is not
permanently implantable, life
[[Page 12744]]
supporting, or life sustaining, if FDA finds that such a device should
be subject to part 803 in order to protect the public health (section
519(a)(1)(B)(i)(III) of the FD&C Act). If such class I or class II
devices are not the subject of an FDA notice or letter, the malfunction
reports for these devices are to be submitted in accordance with the
criteria established by the Secretary (and, by delegation, FDA), which
criteria shall require the reports to be in summary form and made on a
quarterly basis (section 519(a)(1)(B)(ii) of the FD&C Act).
Under section 519(a) of the FD&C Act, as amended by FDAAA, there is
no change to the obligation for an importer to submit malfunction
reports to the manufacturer in accordance with part 803 for devices
that it imports into the United States (section 519(a)(1)(B)(iii) of
the FD&C Act).
FDA intends to provide notice in the Federal Register that lists
the types of devices that should be subject to part 803 in order to
protect the public health, as required by section 519(a)(1)(B)(i)(III)
of the FD&C Act). In addition, FDA intends to, by rulemaking, establish
malfunction reporting criteria for devices subject to section
519(a)(1)(B)(ii) of the FD&C Act. In the interim, in the interest of
public health, FDA is publishing this notice under section
519(a)(1)(B)(i)(III), to clarify that, to the extent there is any
confusion as to current malfunction reporting requirements, all device
manufacturers and importers of class I and those class II devices that
are not permanently implantable, life supporting, or life sustaining,
must continue to report in full compliance with part 803, pending
further FDA notice under section 519(a)(1)(B)(i)(III), as to specific
devices or device types subject to part 803, and the establishment of
criteria in accordance with section 519(a)(1)(B)(ii). FDA considers it
necessary to subject all such devices to part 803 in the interim, in
order to protect the public health by ensuring that there is no gap in
malfunction reporting for any device.
II. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. It is no
longer necessary to send two copies of mailed comments. Identify
comments with the docket number found in brackets in the heading of
this document. Received comments may be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: March 2, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-5146 Filed 3-7-11; 8:45 am]
BILLING CODE 4160-01-P